Leerink Partnrs Predicts Weaker Earnings for Exact Sciences

Exact Sciences Co. (NASDAQ:EXASFree Report) – Equities research analysts at Leerink Partnrs dropped their Q4 2025 earnings per share estimates for Exact Sciences in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.14 per share for the quarter, down from their prior forecast of $0.22. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.87) per share.

Exact Sciences (NASDAQ:EXASGet Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year.

EXAS has been the topic of several other research reports. BTIG Research cut their price target on Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday. Wells Fargo & Company assumed coverage on Exact Sciences in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $75.00 price target on the stock. Piper Sandler boosted their price target on Exact Sciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, September 12th. The Goldman Sachs Group cut their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Raymond James reissued a “market perform” rating on shares of Exact Sciences in a report on Thursday, September 26th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.06.

Check Out Our Latest Stock Report on EXAS

Exact Sciences Trading Down 23.5 %

NASDAQ:EXAS opened at $54.72 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. Exact Sciences has a one year low of $40.62 and a one year high of $79.62. The business’s 50-day simple moving average is $67.14 and its 200 day simple moving average is $56.65. The stock has a market cap of $10.11 billion, a price-to-earnings ratio of -57.00 and a beta of 1.27.

Insider Activity

In other news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares of the company’s stock, valued at approximately $893,060. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.36% of the company’s stock.

Hedge Funds Weigh In On Exact Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXAS. Private Advisor Group LLC grew its holdings in Exact Sciences by 12.5% in the 1st quarter. Private Advisor Group LLC now owns 26,974 shares of the medical research company’s stock worth $1,863,000 after buying an additional 2,999 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in Exact Sciences by 1.7% in the 1st quarter. Daiwa Securities Group Inc. now owns 11,947 shares of the medical research company’s stock worth $825,000 after buying an additional 200 shares in the last quarter. Motive Wealth Advisors bought a new position in Exact Sciences in the 1st quarter worth approximately $201,000. Oppenheimer & Co. Inc. grew its holdings in Exact Sciences by 1.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 23,088 shares of the medical research company’s stock worth $1,594,000 after buying an additional 401 shares in the last quarter. Finally, ClariVest Asset Management LLC grew its holdings in Exact Sciences by 32.4% in the 1st quarter. ClariVest Asset Management LLC now owns 25,313 shares of the medical research company’s stock worth $1,748,000 after buying an additional 6,192 shares in the last quarter. 88.82% of the stock is owned by institutional investors.

About Exact Sciences

(Get Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Articles

Earnings History and Estimates for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.